Letter: ustekinumab for the treatment of post‐surgical and refractory Crohn's disease
- 11 March 2021
- journal article
- letter
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 53 (7) , 859-860
Abstract
LINKED CONTENTThis article is linked to Biemans et al paper. To view this article, visit https://doi.org/10.1111/apt.15745Keywords
This publication has 3 references indexed in Scilit:
- Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentAlimentary Pharmacology & Therapeutics, 2020
- Crohn’s diseaseNature Reviews Disease Primers, 2020
- Predictability of the postoperative course of Crohn's diseaseGastroenterology, 1990